ArriVent BioPharma (AVBP) Insider Hohneker Buys 13,562 Shares

On June 18, 2026, John Hohneker purchased 13,562 shares of AVBP. This insider transaction was not part of a pre-planned trading program and reflects a direct acquisition of shares.

Other Institutional Activity in AVBP

Several institutional investors have recently adjusted their holdings in AVBP. Suvretta Capital Management, LLC increased its position by 295,048 shares, bringing its total to over 4.4 million shares valued at approximately $101.5 million. Infinitum Asset Management, LLC added 25,000 shares, reaching a total of around 4.1 million shares worth $95.7 million. Meanwhile, FMR LLC reduced its stake by 687,440 shares, leaving it with about 3 million shares valued at $69.6 million. BlackRock, Inc. also grew its holdings by 157,463 shares to a total of 2.5 million shares, valued at approximately $58.4 million.

ArriVent BioPharma, Inc. Stock Up 13.1%

Shares of AVBP traded near $31.74 on Tuesday. The stock has been a focus for institutional investors, with BlackRock and Suvretta Capital Management making notable adjustments to their positions. Analysts maintain a positive outlook on AVBP, with several firms reiterating their 'buy' ratings.

Insider Buying and Selling at ArriVent BioPharma, Inc.

In addition to John Hohneker, several other insiders purchased shares on June 18, 2026. Chris Nolet, Kristine Peterson, and Merdad Parsey each bought 13,562 shares. Earlier this year, on February 2, James Paul Kastenmayer, General Counsel, and Winston Kung, Chief Financial Officer, made significant purchases of 130,000 and 140,000 shares, respectively.

Analysts Set New Price Targets

Analysts remain optimistic about AVBP's prospects. On May 29, 2026, Truist Securities maintained a 'buy' rating with a price target of $45. Citigroup has consistently supported a 'buy' rating, with targets ranging from $33 to $45 in recent months. The consensus among analysts is a 'buy' recommendation, with the average price target reflecting a positive outlook.

Bottom Line

John Hohneker's recent purchase of AVBP shares adds to the insider buying activity, indicating a potential vote of confidence in the company's future. Institutional investors have also been active, with some increasing and others reducing their stakes. Analysts continue to support a 'buy' rating, suggesting optimism about AVBP's performance. As always, these insights are based on past filings and transactions, and the actual current holdings may differ.